###begin article-title 0
Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis
###end article-title 0
###begin p 1
###xml 938 943 <span type="species:ncbi:9606">human</span>
###xml 1313 1321 <span type="species:ncbi:9606">patients</span>
Atherosclerosis is an inflammatory vascular disease responsible for the first cause of mortality worldwide. Recent studies have clearly highlighted the critical role of the immunoinflammatory balance in the modulation of disease development and progression. However, the immunoregulatory pathways that control atherosclerosis remain largely unknown. We show that loss of suppressor of cytokine signaling (SOCS) 3 in T cells increases both interleukin (IL)-17 and IL-10 production, induces an antiinflammatory macrophage phenotype, and leads to unexpected IL-17-dependent reduction in lesion development and vascular inflammation. In vivo administration of IL-17 reduces endothelial vascular cell adhesion molecule-1 expression and vascular T cell infiltration, and significantly limits atherosclerotic lesion development. In contrast, overexpression of SOCS3 in T cells reduces IL-17 and accelerates atherosclerosis. We also show that in human lesions, increased levels of signal transducer and activator of transcription (STAT) 3 phosphorylation and IL-17 are associated with a stable plaque phenotype. These results identify novel SOCS3-controlled IL-17 regulatory pathways in atherosclerosis and may have important implications for the understanding of the increased susceptibility to vascular inflammation in patients with dominant-negative STAT3 mutations and defective Th17 cell differentiation.
###end p 1
###begin p 2
###xml 134 153 134 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Binder et al., 2002</xref>
###xml 155 178 155 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Hansson and Libby, 2006</xref>
###xml 180 203 180 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Tedgui and Mallat, 2006</xref>
###xml 205 223 205 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">Weber et al., 2008</xref>
###xml 367 390 367 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Tedgui and Mallat, 2006</xref>
The immunoinflammatory response plays a prominent role in driving atherosclerotic lesion development, progression, and complications (Binder et al., 2002; Hansson and Libby, 2006; Tedgui and Mallat, 2006; Weber et al., 2008). Defining the direct roles of specific immune regulatory pathways in the modulation of atherosclerosis is certainly of considerable interest (Tedgui and Mallat, 2006).
###end p 2
###begin p 3
###xml 188 210 188 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Yoshimura et al., 2007</xref>
###xml 407 424 407 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Tang et al., 2005</xref>
###xml 426 446 426 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Gharavi et al., 2007</xref>
###xml 448 472 448 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Ortiz-Mu&#241;oz et al., 2009</xref>
Suppressor of cytokine signaling (SOCS) proteins are key physiological regulators of both innate and adaptive immunity, and control the development of various immunoinflammatory diseases (Yoshimura et al., 2007). SOCS3 is expressed in atherosclerotic lesions, and the current paradigm suggests an atheroprotective role through inhibition of STAT3 signaling and the suppression of proinflammatory responses (Tang et al., 2005; Gharavi et al., 2007; Ortiz-Munoz et al., 2009). However, its direct role in the control of the immune response of atherosclerosis is still largely unknown.
###end p 3
###begin p 4
###xml 283 302 283 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Kinjyo et al., 2006</xref>
###xml 420 437 420 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Chen et al., 2006</xref>
###xml 530 540 530 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Dong, 2008</xref>
###xml 625 643 625 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Maron et al., 2002</xref>
###xml 645 664 645 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Mallat et al., 2003</xref>
###xml 777 793 777 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Eid et al., 2009</xref>
###xml 1045 1066 1045 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Bettelli et al., 2007</xref>
###xml 1068 1090 1068 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Yoshimura et al., 2007</xref>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
Recent studies have addressed the role of T cell-specific SOCS3 expression on T cell differentiation and cytokine production. Intriguingly, one study reported preferential Th3- and/or Tr1-like differentiation and reduced Th1 polarization in mice lacking SOCS3 expression in T cells (Kinjyo et al., 2006). However, others have reported a preferential promotion of Th17 in the absence of T cell-specific SOCS3 expression (Chen et al., 2006), consistent with the critical role of STAT3 activation in Th17 development (for review see Dong, 2008). Tr1-related responses have been associated with the reduction of atherosclerosis (Maron et al., 2002; Mallat et al., 2003), whereas recent studies have indirectly associated IL-17 production with potentially proatherogenic responses (Eid et al., 2009). Still, the direct roles of SOCS3 and IL-17 production in the modulation of vascular inflammation and atherosclerotic lesion development remain unknown. The involvement of SOCS3- and IL-17-related signaling pathways in various inflammatory diseases (Bettelli et al., 2007; Yoshimura et al., 2007) will certainly promote the development of therapeutic strategies aiming at the modulation of these pathways to limit disease severity and progression. Whether modulation of SOCS3 and IL-17 production would similarly alter the inflammatory process related to atherosclerosis remains unknown. We have therefore designed a series of experiments to directly assess the roles of T cell-specific SOCS3 and (SOCS3-controlled) IL-17 in the modulation of vascular inflammation and atherosclerotic lesion development.
###end p 4
###begin title 5
RESULTS AND DISCUSSION
###end title 5
###begin title 6
SOCS3 expression in T cells significantly affects atherosclerotic lesion development
###end title 6
###begin p 7
###xml 162 165 162 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 158 165 158 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 464 485 464 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">Yasukawa et al., 2003</xref>
###xml 487 506 487 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Kinjyo et al., 2006</xref>
###xml 947 955 947 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 a</xref>
###xml 1205 1208 1201 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1201 1208 1197 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
###xml 668 672 <span type="species:ncbi:10090">mice</span>
###xml 695 699 <span type="species:ncbi:10090">mice</span>
###xml 918 922 <span type="species:ncbi:10090">mice</span>
###xml 1209 1213 <span type="species:ncbi:10090">mice</span>
We first examined the effect of SOCS3 deletion in T cells on the development of atherosclerosis. We reconstituted low-density lipoprotein receptor-deficient (Ldlr-/-) mice with either a WT bone marrow from SOCS3flox/flox mice (the reconstituted mice are designated SOCS3-WT) or a bone marrow from mice with T cell-specific deletion in SOCS3 (SOCS3flox/flox:Lck-Cre) generated by a conditional gene targeting approach using a Cre-loxP system (designated SOCS3-cKO; Yasukawa et al., 2003; Kinjyo et al., 2006). Phosphorylated (P)-STAT3 was readily detectable in atherosclerotic lesions, and we found a marked increase in P-STAT3 in spleen-derived T cells from SOCS3-cKO mice compared with SOCS-WT mice (), indicating an efficient and functional deletion of SOCS3 in T cells. We therefore quantified lesion size after 6 wk on a high fat diet. We found an unexpected 50% reduction of aortic sinus lesion size in SOCS3-cKO mice compared with controls (Fig. 1 a), despite similar plasma cholesterol levels (18.4 +/- 0.7 vs. 17.6 +/- 0.5 g/liter; P = 0.32). We observed a similar protection against atherosclerosis at the levels of the aortic sinus and the descending thoracic aorta in a separate set of old Ldlr-/- mice reconstituted with SOCS3-cKO bone marrow (Fig. S1 d).
###end p 7
###begin p 8
###xml 0 140 0 140 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS3 deletion in T cells promotes IL-17 and IL-10 production, inhibits macrophage apoptosis, and limits atherosclerotic lesion development.</bold>
###xml 208 211 208 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 204 211 204 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 566 567 560 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 859 860 849 850 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 233 237 <span type="species:ncbi:10090">mice</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
###xml 774 778 <span type="species:ncbi:10090">mice</span>
###xml 893 897 <span type="species:ncbi:10090">mice</span>
SOCS3 deletion in T cells promotes IL-17 and IL-10 production, inhibits macrophage apoptosis, and limits atherosclerotic lesion development. (a) Atherosclerotic lesion size in the aortic root of chimeric Ldlr-/- SOCS3-WT or SOCS-cKO mice. Data are representative of four independent experiments throughout this work. Dashed lines indicate mean values. (b) Lesion T cell infiltration (red staining; mean values +/- SEM). Data are representative of three experiments. (c) Reduced IFN-gamma but increased IL-10 and IL-17 production in supernatants of CD3-stimulated CD4+ T cells (means +/- SEM of five mice per group and two experiments; *, P < 0.05). (d) Necrotic core (nc; trichrome staining) size (means +/- SEM) in the aortic root. Representative of two experiments and 13 mice per group. (e) Macrophage apoptosis (TUNEL staining) after coincubation with CD4+ cells from SOCS3-WT or SOCS-cKO mice (means +/- SEM). Representative of three experiments (*, P < 0.05). Bars: (a) 250 microm; (b) 30 microm; (d) 60 microm.
###end p 8
###begin p 9
###xml 133 136 133 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 129 136 129 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apoe<sup>&#8722;/&#8722;</sup></italic>
###xml 141 144 141 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 137 144 137 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag2<sup>&#8722;/&#8722;</sup></italic>
###xml 167 168 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 231 248 231 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Seki et al., 2003</xref>
###xml 378 379 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 414 415 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 669 686 669 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Seki et al., 2003</xref>
###xml 688 707 688 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">Tanaka et al., 2008</xref>
###xml 776 779 776 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 772 779 772 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apoe<sup>&#8722;/&#8722;</sup></italic>
###xml 784 787 784 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 780 787 780 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag2<sup>&#8722;/&#8722;</sup></italic>
###xml 813 814 813 814 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 225 229 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
###xml 663 667 <span type="species:ncbi:10090">mice</span>
###xml 788 792 <span type="species:ncbi:10090">mice</span>
We then tested the effect of SOCS3 overexpression in T cells on the development of atherosclerosis (Fig. S1 e). We reconstituted Apoe-/-/Rag2-/- mice with purified CD4+ cells recovered from either WT or SOCS3-transgenic (Tg) mice (Seki et al., 2003). As expected, we found reduced P-STAT3 in SOCS3-Tg T cells (unpublished data). After 6 wk of a high fat diet, spleen-derived CD4+ cells of mice transferred with CD4+ SOCS3-Tg cells showed reduced production of IL-17 and IL-10 but enhanced production of IL-4 (Fig. S1 e). This is consistent with previous studies that showed reduced Th17 and preferential Th2 cell differentiation of T cells isolated from SOCS3-Tg mice (Seki et al., 2003; Tanaka et al., 2008). Interestingly, we found a fourfold increase of lesion size in Apoe-/-/Rag2-/- mice transferred with CD4+ SOCS3-Tg cells compared with controls (Fig. S1 e), despite similar plasma cholesterol levels (12.1 +/- 1.6 vs. 14.1 +/- 0.78 g/liter; P = 0.25). Thus, SOCS3 expression in T cells significantly affects atherosclerotic lesion development.
###end p 9
###begin title 10
SOCS3 deletion in T cells enhances IL-10 and IL-17 production
###end title 10
###begin p 11
###xml 137 145 137 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 b</xref>
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 278 279 278 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 408 409 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 542 550 538 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 c</xref>
###xml 728 747 724 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Kinjyo et al., 2006</xref>
###xml 852 853 848 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 959 967 955 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 c</xref>
###xml 969 985 965 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Chen et al. 2006</xref>
###xml 987 997 983 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Dong, 2008</xref>
###xml 1238 1239 1230 1231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1310 1330 1302 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Lochner et al., 2008</xref>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 331 335 <span type="species:ncbi:10090">mice</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
###xml 1463 1467 <span type="species:ncbi:10090">mice</span>
The reduction of atherosclerosis in SOCS3-cKO mice was associated with a significant decrease of T cell infiltration within the lesions (Fig. 1 b), suggesting a modulation of the T cell phenotype. We found no difference in the number and suppressive function of natural CD4+CD25+Foxp3+ regulatory T cells between the two groups of mice (). Thus, we analyzed cytokine production by purified spleen-derived CD4+ cells. We observed a significant reduction of IFN-gamma production and an increase of IL-10 by cells recovered from SOCS3-cKO mice (Fig. 1 c), which was consistent with previous results showing preferential Th3- and/or Tr1-like differentiation and reduced Th1 polarization in mice lacking SOCS3 expression in T cells (Kinjyo et al., 2006). However, we also detected a threefold increase in IL-17 production by the purified SOCS3-deficient CD4+ cells compared with controls, consistent with the critical role of STAT3 activation in Th17 development (Fig. 1 c; Chen et al. 2006; Dong, 2008). Flow cytometry analysis on freshly isolated cells showed no cells expressing both IL-17 and IL-10, suggesting that in vivo, IL-10 and IL-17 are produced by distinct T cells, which is in agreement with a recent study showing that RORgammat+ T cells producing both IL-10 and IL-17 could not be observed in vivo (Lochner et al., 2008). Consistent with enhanced IL-17 production, we found increased IL-6 but reduced IL-27 levels in the circulating blood of SOCS3-cKO mice (Fig. S2 c). We also found increased production of IL-6 by cultured SOCS3-cKO splenocytes. IL-6 neutralization did not alter IL-17 production, indicating that the Th17 profile of SOCS3-cKO cells was independent of IL-6 (Fig. S2 d). Thus, our results indicate that in the absence of SOCS3 expression in T cells, there is a preferential switch toward increased production of both IL-10 and IL-17, which helps explain seemingly divergent previous results on Th3, Tr1, and Th17 cells.
###end p 11
###begin title 12
SOCS3 deletion in T cells induces an antiinflammatory phenotype in macrophages
###end title 12
###begin p 13
###xml 378 401 378 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Hansson and Libby, 2006</xref>
###xml 657 658 649 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 892 900 884 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 d</xref>
###xml 1158 1159 1150 1151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1192 1193 1184 1185 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1201 1209 1193 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 e</xref>
###xml 1425 1426 1417 1418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1477 1478 1469 1470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1486 1494 1478 1486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 a</xref>
###xml 1795 1803 1787 1795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 a</xref>
###xml 1950 1958 1942 1950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 a</xref>
###xml 2075 2090 2067 2082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, c and d</xref>
###xml 2222 2230 2214 2222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 e</xref>
###xml 2617 2634 2609 2626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Wang et al., 2004</xref>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
###xml 886 890 <span type="species:ncbi:10090">mice</span>
It was remarkable that the loss of SOCS3 in one cell type has produced significant effects on lesion development, where many other cell types are involved. Thus, we hypothesized that the T cell cytokine profile induced by SOCS3 deletion may modulate the inflammatory response of other cell types. In this regard, the innate immune system plays a critical role in atherogenesis (Hansson and Libby, 2006). Therefore, we examined the impact of SOCS3 deletion in T cells on macrophage infiltration and activation. The extent of lesion macrophage accumulation was not altered in SOCS3-cKO compared with SOCS3-WT mice (35,022 +/- 6,308 vs. 36,635 +/- 5,223 microm2; P = 0.84). We hypothesized that this could be related to a differential modulation of macrophage survival within the lesions. Interestingly, we found a marked reduction in the size of the necrotic core in lesions of SOCS3-cKO mice (Fig. 1 d). This was confirmed by the reduction of lesion Tdt-mediated dUTP-biotin nick-end labeling (TUNEL) staining (unpublished data) and a protection against macrophage apoptosis when bone marrow-derived macrophages were incubated in the presence of SOCS3-cKO CD4+ cells compared with SOCS3-WT CD4+ cells (Fig. 1 e). Macrophage death within the lesions is highly promoted by proinflammatory signals. We found a significant reduction of IL-12 and an increase in IL-10 production by macrophages after coincubation with SOCS3-cKO CD4+ cells compared with coincubation with SOCS3-WT CD4+ cells (Fig. 2 a). In addition, we found a significant reduction in the expression of NOS2 and TNF, and an increase of arginase-1 after coincubation of macrophages with SOCS3-cKO T cells compared with SOCS3-WT cells, consistent with a limitation of M1 phenotype and the preservation of an antiinflammatory potential (Fig. 2 a). These effects persisted when T cells and macrophages were physically separated using Transwells, suggesting the involvement of soluble factors (Fig. 2 a). Neutralization of IL-10 production and, to a lesser extent IL-17, prevented some of the antiinflammatory effects (Fig. 2, c and d), whereas incubation with IL-10 was associated with an antiinflammatory phenotype that persisted after supplementation with IL-17 (Fig. 2 e). Our results indicate that SOCS3 signaling in T cells not only affects the T cell phenotype but also regulates the production of pro- and antiinflammatory/atherogenic mediators by macrophages. This is consistent with a study showing that STAT3 activity in tumor cells mediates immune evasion through blockade of inflammatory signal production by the innate and adaptive immune system (Wang et al., 2004). Further studies will be necessary to identify the soluble factors responsible for the full change in macrophage phenotype.
###end p 13
###begin p 14
###xml 0 76 0 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS3 deletion in T cells promotes an antiinflammatory macrophage phenotype.</bold>
###xml 150 151 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 454 455 448 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 756 757 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 184 188 <span type="species:ncbi:10090">mice</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
SOCS3 deletion in T cells promotes an antiinflammatory macrophage phenotype. (a) IL-12 and IL-10 production by macrophages after coincubation with CD4+ cells from SOCS3-WT or SOCS-cKO mice in the presence or absence of Transwells. Mean values +/- SEM of three to four mice per group are shown (*, P < 0.05). (b) TNF-alpha, NOS2, and arginase-1 mRNA expression (arbitrary units relative to GAPDH mRNA expression) by macrophages after coincubation with CD4+ cells. Mean values +/- SEM of three to four mice per group and three independent experiments are shown (*, P < 0.05). (c and d) Quantitative analysis (relative to incubation without neutralizing antibodies) of NOS2, arginase-1, and TNF-alpha mRNA expression in macrophages after coincubation with CD4+ cells in the presence of either anti-IL-10 (c) or anti-IL-17 (d) neutralizing antibodies. (e) Quantitative analysis (relative to control without incubation with recombinant cytokines) of arginase-1 and TNF-alpha mRNA expression in macrophages after incubation with IL-10, IL-17 or IL-10, and IL-17. Values in c-e represent mean values +/- SEM of three mice per group and three different experiments.
###end p 14
###begin title 15
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Neutralization of IL-17 abrogates atheroprotection in mice with T cell-specific SOCS3 deletion and enhances vascular inflammation
###end title 15
###begin p 16
###xml 263 286 255 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Tedgui and Mallat, 2006</xref>
###xml 523 526 515 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 519 526 511 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 648 678 640 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">Uyttenhove and Van Snick, 2006</xref>
###xml 680 703 672 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Uyttenhove et al., 2007</xref>
###xml 1051 1066 1043 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, a and c</xref>
###xml 1246 1254 1238 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 f</xref>
###xml 1360 1375 1352 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, b and d</xref>
###xml 1463 1464 1455 1456 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1472 1480 1464 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 e</xref>
###xml 2159 2189 2143 2173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Schnyder-Candrian et al., 2006</xref>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
###xml 596 601 <span type="species:ncbi:10090">mouse</span>
###xml 850 854 <span type="species:ncbi:10090">mice</span>
###xml 1354 1358 <span type="species:ncbi:10090">mice</span>
###xml 1738 1742 <span type="species:ncbi:10090">mice</span>
The reduction of atherosclerosis in SOCS3-cKO mice was associated with a reduction in IFN-gamma and an increase in both IL-10 and IL-17. The pro- and antiatherogenic roles of IFN-gamma and IL-10, respectively, have been extensively addressed in previous studies (Tedgui and Mallat, 2006). However, the role of IL-17 in atherosclerosis is still unexplored. Thus, we examined the direct role of IL-17 production in the atheroprotective effect of T cell-specific SOCS3 deletion. We generated additional series of chimeric Ldlr-/- mice that were put on a high fat diet and were treated with either a mouse monoclonal anti-IL-17A neutralizing antibody (Uyttenhove and Van Snick, 2006; Uyttenhove et al., 2007) or an isotype-matched control for 6 wk (see Materials and methods). Interestingly, neutralization of IL-17 did not alter lesion size in SOCS3-WT mice, which are highly Th1 biased and produce low levels of IL-17, but totally abrogated the atheroprotective effect of T cell-specific SOCS3 deletion and led to a marked increase of lesion formation (Fig. 3, a and c). Acceleration of lesion development was associated with a marked increase in vascular inflammation, as revealed by increased vascular cell adhesion molecule (VCAM)-1 expression (Fig. 3 f), marked T cell infiltration within the lesions and the adventitia of anti-IL-17-treated SOCS3-cKO mice (Fig. 3, b and d), and a switch toward reduced IL-10 and increased IL-4 production by spleen-derived CD4+ cells (Fig. 3 e) but no change in IFN-gamma (15.4 +/- 0.5 vs. 12.7 +/- 1.1 ng/ml in SOCS3-WT and SOCS3-cKO, respectively). Regulatory T cell function was not altered by anti-IL-17 treatment (not depicted), and the proatherogenic effect of IL-17 neutralization in SOCS3-cKO mice was not prevented by IL-10 supplementation (). These results identify an unprecedented role for SOCS3-controlled IL-17 in the control of vascular inflammation and T cell accumulation within atherosclerotic lesions, which profoundly affects lesion development. Our results are in agreement with a study showing that IL-17 neutralization was associated with enhanced T cell infiltration in a model of allergic asthma (Schnyder-Candrian et al., 2006).
###end p 16
###begin p 17
###xml 0 112 0 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS3-controlled IL-17 production protects against vascular inflammation and atherosclerotic lesion development.</bold>
###xml 308 311 308 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 304 311 304 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 443 444 443 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 673 674 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 736 739 736 739 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 732 739 732 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 932 933 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 333 337 <span type="species:ncbi:10090">mice</span>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
###xml 740 744 <span type="species:ncbi:10090">mice</span>
###xml 817 821 <span type="species:ncbi:10090">mice</span>
###xml 940 944 <span type="species:ncbi:10090">mice</span>
SOCS3-controlled IL-17 production protects against vascular inflammation and atherosclerotic lesion development. Representative photomicrographs (a and b) and quantitative analysis (c and d) of atherosclerotic lesion size (a and c) and lesion T cell infiltration (b and d) in the aortic root of chimeric Ldlr-/- SOCS3-WT or SOCS-cKO mice treated either with a neutralizing anti-IL-17A antibody (anti-IL-17) or an isotype-matched control (IgG; n = 7-8 mice per group). The anti-IL-17 in vivo experiment was repeated twice. p-values are shown in c and d. Dashed lines indicate mean values. (e) Increased IL-4 but reduced IL-10 production in supernatants of CD3-stimulated CD4+ T cells recovered at the time of sacrifice from chimeric Ldlr-/- mice treated with a neutralizing anti-IL-17A antibody. Means +/- SEM of five mice per group performed in triplicates are shown (*, P < 0.05). (f) VCAM-1 expression in atherosclerotic lesions (n = 6-8 mice per group and two separate experiments; *, P < 0.05). Bars: (a) 250 microm; (b) 100 microm; (f) 130 microm.
###end p 17
###begin title 18
###xml 39 42 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
In vivo administration of IL-17 to Ldlr-/- mice reduces endothelial VCAM-1 expression, vascular T cell infiltration, and atherosclerotic lesion development
###end title 18
###begin p 19
###xml 128 134 128 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3</xref>
###xml 418 421 418 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 414 421 414 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 1143 1151 1139 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 a</xref>
###xml 1231 1234 1227 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1227 1234 1223 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 1241 1249 1237 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 a</xref>
###xml 1416 1424 1412 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 b</xref>
###xml 1480 1488 1476 1484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 c</xref>
###xml 1564 1572 1560 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 d</xref>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 490 495 <span type="species:ncbi:10090">mouse</span>
###xml 760 764 <span type="species:ncbi:10090">mice</span>
###xml 913 917 <span type="species:ncbi:10090">mice</span>
###xml 1112 1116 <span type="species:ncbi:10090">mice</span>
###xml 1235 1239 <span type="species:ncbi:10090">mice</span>
Neutralization of IL-17 accelerated atherosclerosis in SOCS3-cKO mice but had no effect on lesion development in SOCS3-WT mice (Fig. 3). We reasoned that this apparent discrepancy might be caused by the low level of IL-17 production by SOCS3-WT T cells (highly Th1 biased on a C57BL/6 background) and that supplementation of SOCS3-WT mice with IL-17 might inhibit lesion development. Thus, we fed 17-wk-old female Ldlr-/- mice a high fat diet and treated them with either rIL-17 or control mouse serum albumin. Administration of rIL-17 led to a significant elevation of circulating IL-17 levels (Fig. S3 c) and to a moderate but significant elevation of IL-6 production (27.5 +/- 18.7 vs. 1 +/- 0.6 pg/ml; P = 0.008) comparable to levels detected in SOCS3-cKO mice, suggesting biological effects. We found no change in T cell cytokine profile (Fig. S3 d) or splenocyte inflammatory response (unpublished data) in mice treated with rIL-17, indicating that at this dosage, IL-17 did not promote inflammatory cell activation. Interestingly, we found a significant reduction of atherosclerotic lesion development in mice supplemented with rIL-17 (Fig. 4 a). We reproduced the results in a different set of younger 12-wk-old female Ldlr-/- mice (Fig. 4 a). Of note, atheroprotection was associated with a marked inhibition of vascular inflammation as revealed by a significant inhibition of vascular T cell infiltration (Fig. 4 b) and a 60% reduction of endothelial VCAM-1 expression (Fig. 4 c). rIL-17 also reduced IL-1-induced endothelial VCAM-1 expression in vitro (Fig. 4 d). These results indicate that IL-17 inhibits high fat-induced vascular inflammation and atherosclerotic lesion development.
###end p 19
###begin p 20
###xml 0 103 0 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementation with IL-17 reduces vascular inflammation and limits atherosclerotic lesion development.</bold>
###xml 189 192 189 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 184 192 184 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr <sup>&#8722;/&#8722;</sup></italic>
###xml 202 206 <span type="species:ncbi:10090">mice</span>
###xml 590 594 <span type="species:ncbi:10090">mice</span>
###xml 782 787 <span type="species:ncbi:10090">mouse</span>
Supplementation with IL-17 reduces vascular inflammation and limits atherosclerotic lesion development. (a) Atherosclerotic lesion size in the aortic root of 17-wk-old female chimeric Ldlr -/- SOCS3-WT mice fed a high fat diet and treated with rIL-17 or control serum albumin for 5 wk. Two different experiments are depicted with eight to nine animals in each group. Young animals were 12 wk old. (b) Lesion and adventitial T cell infiltration in 17-wk-old animals. Similar results were obtained in young animals (not depicted). (c) Endothelial VCAM-1 expression in IL-17-treated 17-wk-old mice. Results represent two separate experiments. (d) One representative example out of three different experiments of a Western blot showing reduction of IL-1-induced VCAM-1 expression after mouse endothelial cells are incubated with IL-17. Dashed lines indicate mean values. Bars: (a) 250 microm; (b) 50 microm; (c) 25 microm.
###end p 20
###begin title 21
Vascular expression of IL-17 and P-Stat3 is associated with plaque stability
###end title 21
###begin p 22
###xml 73 76 73 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 276 277 276 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 341 347 341 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5</xref>
###xml 641 647 641 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5</xref>
###xml 751 757 751 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5</xref>
###xml 936 939 936 939 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 932 939 932 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 335 339 <span type="species:ncbi:10090">mice</span>
###xml 821 826 <span type="species:ncbi:10090">mouse</span>
###xml 940 944 <span type="species:ncbi:10090">mice</span>
We then examined IL-17 expression in mouse atherosclerotic arteries (Ldlr-/- mice reconstituted with SOCS3-WT or SOCS3-cKO) using immunohistochemistry. As expected, we were unable to detect IL-17 expression in T cells of SOCS3-WT mice (not depicted), and only occasional IL-17+ inflammatory cells were detected in lesions of SOCS3-cKO mice (Fig. 5, left, a and b), which may be explained, at least in part, by the low number of activated SOCS3-deficient T cells that infiltrated the lesions. Unexpectedly, we found a marked staining of IL-17 in medial smooth muscle cells (SMCs) of plaque-free areas (which was confirmed in normal arteries; Fig. 5, left, e), and the staining appeared to be rapidly lost in medial SMCs underlying early lipid lesions (Fig. 5, left, c and d). We confirmed the detection of IL-17 in normal mouse aorta by Western blotting using a different antibody (unpublished data). These results show that C57BL/6 Ldlr-/- mice, which are Th1 biased, produce low levels of IL-17 in T cells and that vascular wall production of IL-17 decreases during the development of atherosclerosis, suggesting a relationship between SMC differentiation and IL-17 expression.
###end p 22
###begin p 23
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Expression of IL-17 in atherosclerotic vessels.</bold>
###xml 55 60 <span type="species:ncbi:10090">Mouse</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 665 669 <span type="species:ncbi:10090">mice</span>
###xml 802 806 <span type="species:ncbi:10090">mice</span>
###xml 861 866 <span type="species:ncbi:10090">mouse</span>
###xml 925 930 <span type="species:ncbi:9606">Human</span>
###xml 1592 1597 <span type="species:ncbi:9606">human</span>
Expression of IL-17 in atherosclerotic vessels. (left) Mouse atherosclerosis. (a and b) Occasional staining for IL-17 (red, arrows) in inflammatory cells within the intima (i) and adventitia (arrows in b) of SOCS3-cKO mice. (c and d) Representative examples of staining for IL-17 (red, arrows) in the media (m) of the aortic sinus (c) and the coronary arteries (d) of SOCS3-cKO mice. Note that IL-17 staining in media was detected in plaque-free areas (right of the arrowheads) and was lost in areas where plaques have developed (left of the arrowheads). (e-g) Staining for IL-17 (red/brown) in the media of the aortic sinus of WT (e and f) or IL-17A-deficient (g) mice. Note that IL-17 staining almost disappeared after adsorption with the IL-17-specific peptide (f) or in vessels of IL-17A-deficient mice (g). Data are representative of at least 10 different mouse arteries. Bars: (a-d) 45 microm; (e-g) 90 microm. (right) Human atherosclerosis. (a) IL-17 staining in the media (m) and adventitia (adv) of carotid plaques. (b) The image is from an area underlying an advanced plaque. It shows IL-17 staining in adventitial vessels (arrows), but the media has lost its IL-17 staining. (c) The image is from an area underlying an early intimal thickening. It shows staining for IL-17 in the adventitial vessels (arrows) and still diffuse moderate IL-17 staining within the media. (d) Another example of IL-17 staining (brown) in an advanced carotid plaque. (e) Disappearance of IL-17 staining after adsorption with the IL-17-specific peptide. Data are representative of at least 10 different human arteries. Bars: (a) 250 microm; (b and c) 30 microm; (d and e) 45 microm.
###end p 23
###begin p 24
###xml 217 218 217 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 243 249 243 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
###xml 272 273 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 308 314 308 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
###xml 380 386 380 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
###xml 600 606 600 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5</xref>
###xml 818 824 818 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
###xml 1055 1061 1055 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 118 126 <span type="species:ncbi:9606">Patients</span>
###xml 228 233 <span type="species:ncbi:9606">human</span>
###xml 506 510 <span type="species:ncbi:10090">mice</span>
Finally, we studied human carotid atherosclerotic arteries retrieved from patients undergoing carotid endarterectomy. Patients characteristics are given in . P-Stat3 and IL-17 expression were readily detectable in CD3+ cells of human plaques (Fig. 6), although not all CD3+ cells expressed IL-17 or P-Stat3 (Fig. 6). We could also detect P-Stat3 in other cell types, as expected (Fig. 6, and not depicted). Interestingly, we also detected IL-17 expression in vascular SMCs, and consistent with our data in mice, we found a clear decrease in its expression by medial SMCs underlying advanced lesions (Fig. 5, right). Interestingly, semiquantitative assessment of P-Stat3 and IL-17 expression showed increased levels of these two markers in plaques with fibrous (stable) compared with atheromatous (unstable) phenotype (Fig. 6). Consistent with this finding, increased levels of P-Stat3 were significantly associated with a low macrophage content, and increased levels of IL-17 were associated with a lower macrophage infiltration and a higher SMC content (Fig. 6). No relation was found between Stat3 or P-Stat1 levels and plaque phenotype (unpublished data).
###end p 24
###begin p 25
###xml 0 132 0 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Stat3 phosphorylation and IL-17 expression in human carotid atherosclerotic plaques are associated with markers of plaque stability.</bold>
###xml 175 176 175 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 255 256 255 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 669 670 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 751 752 749 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 46 51 <span type="species:ncbi:9606">human</span>
###xml 186 191 <span type="species:ncbi:9606">human</span>
###xml 680 685 <span type="species:ncbi:9606">human</span>
Stat3 phosphorylation and IL-17 expression in human carotid atherosclerotic plaques are associated with markers of plaque stability. (a) Stat3 phosphorylation (P-Stat3) in CD3+ cells of human carotid atherosclerotic plaques (arrows). Arrowheads show a CD3+ cell with no P-Stat3. (b) Detection of P-Stat3 in protein extracts from atheromatous (A) or fibrous (F) carotid plaques using Western blotting. Ponceau red is shown for estimation of sample loading. (c) Semiquantitative analysis of P-Stat3 content of carotid plaques and relation to plaque macrophage (MPhi) content, plaque SMC content, and plaque phenotype (atheromatous or fibrous). (d) IL-17 expression in CD3+ cells of human carotid atherosclerotic plaques (arrows). Arrowheads show two CD3+ cells with no IL-17 expression. (e) Detection of IL-17 in protein extracts from atheromatous (A) or fibrous (F) carotid plaques using Western blotting (the same blot shown for P-Stat3 is shown for IL-17). (e) Semiquantitative analysis of the IL-17 content of carotid plaques and the relation to plaque macrophage content, plaque SMC content, and plaque phenotype (atheromatous or fibrous). Overall, 40 different atherosclerotic plaques from 5 separate experiments were studied. Bars: (a) 30 microm; (c) 60 microm. A.U., arbitrary units.
###end p 25
###begin p 26
###xml 244 266 244 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Minegishi et al., 2007</xref>
###xml 290 305 290 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Ma et al., 2008</xref>
###xml 307 326 307 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Milner et al., 2008</xref>
###xml 426 451 426 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">van der Meer et al., 2006</xref>
###xml 453 470 453 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Ling et al., 2007</xref>
###xml 734 754 734 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Freeman et al., 2007</xref>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 453 457 <span type="species:ncbi:163112">Ling</span>
###xml 894 900 <span type="species:ncbi:9606">humans</span>
In conclusion, we show that endogenous expression of SOCS3 in T cells interrupts a major regulatory pathway in atherosclerosis through inhibition of IL-17 production. Interestingly, patients have been identified with defective STAT3 signaling (Minegishi et al., 2007) and IL-17 production (Ma et al., 2008; Milner et al., 2008), and recent observational studies have reported the abnormal occurrence of vascular inflammation (van der Meer et al., 2006; Ling et al., 2007) in this setting despite the absence of classical cardiovascular risk factors. Although the reported vascular abnormalities consisted mainly of inflammatory vascular aneurysms, some cases of coronary atherosclerosis have been reported in these young individuals (Freeman et al., 2007). Thus, our results may have important implications for the understanding of the pathophysiological mechanisms of vascular inflammation in humans and identify novel targets for disease modulation.
###end p 26
###begin title 27
MATERIALS AND METHODS
###end title 27
###begin title 28

###end title 28
###begin title 29
Animals.
###end title 29
###begin p 30
###xml 42 45 42 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 439 460 439 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">Yasukawa et al., 2003</xref>
###xml 910 940 906 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">Uyttenhove and Van Snick, 2006</xref>
###xml 942 965 938 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Uyttenhove et al., 2007</xref>
###xml 1339 1342 1331 1334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1335 1342 1327 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ldlr<sup>&#8722;/&#8722;</sup></italic>
###xml 1555 1558 1543 1546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1551 1558 1539 1546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apoe<sup>&#8722;/&#8722;</sup></italic>
###xml 1563 1566 1551 1554 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1559 1566 1547 1554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag2<sup>&#8722;/&#8722;</sup></italic>
###xml 1715 1716 1703 1704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1720 1721 1708 1709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1813 1830 1801 1818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Seki et al., 2003</xref>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 292 296 <span type="species:ncbi:10090">mice</span>
###xml 486 490 <span type="species:ncbi:10090">mice</span>
###xml 646 650 <span type="species:ncbi:10090">mice</span>
###xml 779 783 <span type="species:ncbi:10090">mice</span>
###xml 885 890 <span type="species:ncbi:10090">mouse</span>
###xml 1116 1120 <span type="species:ncbi:10090">mice</span>
###xml 1138 1143 <span type="species:ncbi:10090">mouse</span>
###xml 1185 1190 <span type="species:ncbi:10090">mouse</span>
###xml 1209 1214 <span type="species:ncbi:10090">mouse</span>
###xml 1350 1354 <span type="species:ncbi:10090">mice</span>
###xml 1372 1377 <span type="species:ncbi:10090">mouse</span>
###xml 1420 1425 <span type="species:ncbi:10090">mouse</span>
###xml 1444 1449 <span type="species:ncbi:10090">mouse</span>
###xml 1567 1571 <span type="species:ncbi:10090">mice</span>
We subjected 12- or 24-wk-old C57BL/6 Ldlr-/- female mice to medullar aplasia by 9.5 Gy of lethal total body irradiation. We repopulated the mice with an intravenous injection of bone marrow cells isolated from femurs and tibias of female C57BL/6 SOCS3-WT mice (SOCS3flox/flox) or littermate mice with a T cell-specific deletion in SOCS3 (SOCS3flox/flox:Lck-Cre) generated by a conditional gene targeting approach using a Cre-loxP system (Yasukawa et al., 2003). The SOCS3fl/fl-Lck-Cre mice were 87.5% C57BL/6 and 12.5% 129 and were intercrossed for >10 generations, indicating that they were on a homogeneous background. After 4 wk of recovery, mice were fed a high fat diet containing 15% fat, 1.25% cholesterol, and 0% cholate for 6 wk. In some experiments, the reconstituted mice received an i.p. injection of either purified neutralizing anti-IL-17A-specific antibody (200 microg/mouse, twice per week; ; Uyttenhove and Van Snick, 2006; Uyttenhove et al., 2007) or IgG1 control for 6 wk. In others experiments using anti-IL-17A antibody or IgG control, we injected i.p. the reconstituted SOCS3flox/flox:Lck-Cre mice with recombinant mouse IL-10 (eBioscience) diluted in PBS 0.05% mouse albumin (2 microg/mouse, twice per week) or PBS 0.05% albumin for 6 wk. In another set of experiments, we treated i.p. 12- or 17-wk-old C57BL/6 Ldlr-/- female mice with recombinant mouse IL-17A (eBioscience) diluted in PBS 0.05% mouse albumin (2 microg/mouse, twice per week) or PBS 0.05% albumin during 5 wk of a high fat diet. Finally, 6-wk-old male C57BL/6 Apoe-/-/Rag2-/- mice (provided by P. Gourdy, Institut National de la Sante et de la Recherche Medicale, Toulouse, France) were transferred intravenously with 3 x 106 CD4+ cells recovered from either C57BL/6 SOCS3-WT or C57BL/6 SOCS3-overexpressing Tg (SOCS3-Tg; Seki et al., 2003), and were put on high fat diet for 6 wk. Experiments were conducted according to the French veterinary guidelines and those formulated by the European Community for experimental animal use (L358-86/609EEC), and were approved by the Institut National de la Sante et de la Recherche Medicale.
###end p 30
###begin title 31
Extent and composition of atherosclerotic lesions.
###end title 31
###begin p 32
###xml 85 103 85 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Taleb et al., 2007</xref>
###xml 187 211 187 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">Ait-Oufella et al., 2007</xref>
###xml 534 556 534 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Takahashi et al., 2008</xref>
###xml 219 224 <span type="species:ncbi:10090">mouse</span>
###xml 346 352 <span type="species:ncbi:9986">rabbit</span>
###xml 470 475 <span type="species:ncbi:9606">human</span>
###xml 476 481 <span type="species:ncbi:10090">mouse</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
Quantification of lesion size and composition was performed as previously described (Taleb et al., 2007). TUNEL staining was performed on fixed cryostat sections as previously described (Ait-Oufella et al., 2007). Anti-mouse VCAM-1 antibody (clone 429) was obtained from BD. Tyrosine 705 phosphorylation of Stat3 was detected in the plaque using rabbit anti-P-Stat3 antibody (Cell Signaling Technology). IL-17 staining in the plaque was performed using a validated anti-human/mouse IL-17 antibody from Santa Cruz Biotechnology, Inc. (Takahashi et al., 2008). The IL-17A-deficient mice were provided by Y. Iwakura (University of Tokyo, Tokyo, Japan).
###end p 32
###begin title 33
Cell recovery and purification, culture, proliferation, and cytokine assays.
###end title 33
###begin p 34
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 11 12 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 31 32 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 156 174 156 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Taleb et al., 2007</xref>
###xml 214 215 214 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 219 220 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 366 367 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD11c+, CD4+CD25+, and CD4+CD25- cells were purified and processed for cell proliferation assays and cytokine production as previously described in detail (Taleb et al., 2007). In some experiments (Fig. S3), 2 x 105 CD4+ T cells per well were stimulated in anti-CD3-coated (2 microg/ml) and anti-CD28-coated (2 microg/ml) microplates for 48 h in the absence of CD11c+ cells. IL-4, IL-10, IL-17, and IFN-gamma productions in the supernatants were measured using specific ELISAs (BD and R&D Systems).
###end p 34
###begin title 35
Flow cytometry.
###end title 35
###begin p 36
###xml 301 302 301 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 159 164 <span type="species:ncbi:10090">mouse</span>
###xml 165 168 <span type="species:ncbi:10116">rat</span>
Splenocytes were labeled with FITC-conjugated anti-CD4 (clone GK1.5; Miltenyi Biotec), and intracellular Foxp3 staining was performed using PE-conjugated anti-mouse/rat Foxp3 (PFJK-16s; eBioscience) according to the manufacturer's instructions (eBioscience). Anti-P-Stat3 staining was performed on CD4+ T cells stimulated with 100 ng/ml IL-6 for 15 min according to the manufacturer's protocol (Cell Signaling Technology). Labeled cells were then analyzed by flow cytometry on a flow cytometer (Epics XL; Beckman Coulter). IL-17 and IL-10 staining was performed using cytokine secretion assay kits (Miltenyi Biotec).
###end p 36
###begin title 37
Western blot analysis.
###end title 37
###begin p 38
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 429 434 <span type="species:ncbi:9606">human</span>
###xml 571 576 <span type="species:ncbi:9606">Human</span>
CD4+ cells were stimulated with coated anti-CD3 and anti-CD28 antibodies (2 microg/ml each) for 60 min. Cells were then processed for Western blot analyses. Membranes were probed with antibodies directed against SOCS3 (clone 1B2; MBL International), P-Stat3 and Stat3 protein (Cell Signaling Technology). On saphenous vein endothelial cell extracts, we quantified VCAM-1 expression by using a specific antibody (R&D Systems). On human plaque extracts, P-Stat3, Stat3, and P-Stat1 staining was performed using specific antibodies purchased from Cell Signaling Technology. Human IL-17 was detected using a monoclonal antibody (clone 41802; R&D Systems).
###end p 38
###begin title 39
T cell-macrophage co-cultures.
###end title 39
###begin p 40
###xml 171 172 171 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 620 650 600 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">Uyttenhove and Van Snick, 2006</xref>
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
Macrophages were prepared from mouse bone marrow. Differentiated macrophages were then cultured in 6-well plates either without T cells or with WT or SOCS3-cKO T cells (106 cells per well) for 24 h in the presence of 1 microg/ml of soluble anti-CD3 antibody, after which the T cells were removed and the different cultures were washed twice with PBS and the macrophages were stimulated for 24 h with 1 microg/ml LPS and 100 U/ml IFN-gamma. In some experiments, SOCS3-WT or SOCS3-cKO T cells were incubated in the presence of the neutralizing antibodies anti-IL-10 (2 microg/ml; R&D Systems) or anti-IL-17 (10 microg/ml; Uyttenhove and Van Snick, 2006), or their corresponding isotype-matched controls. In other experiments, 10 ng/ml of the recombinant proteins IL-10 and/or IL-17 (eBioscience) were added on macrophages for 24 h. Quantitative real-time PCR was performed on an ABI PRISM 7700 (Applied Biosystems) in triplicates. Cycle threshold for GAPDH (primers: GAPDH-R, 5'-CGTCCCGTAGACAAAATGGTGAA-3'; GAPDH-L, 5'-GCCGTGAGTGGAGTCATACTGGAACA-3') was used to normalize gene expression. Primer sequences of M1 macrophage markers (NOS2 and TNF-alpha) and M2 marker (arginase-1) are as follows: NOS2-R, 5'-CCAAGCCCTCACCTACTTCC-3'; NOS2-L, 5'-CTCTGAGGGCTGACACAAGG-3'; TNF-alpha-R, 5'-GTAGCCCACGTCGTAGCAAAC-3'; TNF-alpha-L, 5'-CTGGCACCACTAGTTGGTTGTC-3'; Arg-1-R, 5'-CTCCAAGCCAAAGTCCTTAGAG-3'; Arg-1-L, 5'-AGGAGCTGTCATTAGGGACATC-3'). PCR conditions were 10 min at 95degreesC; 35 cycles of 95degreesC for 15 s, 60degreesC for 20 s, and 72degreesC for 20 s; and a final extension at 72degreesC for 20 s. On supernatants, ELISAs were performed to measure IL-10 and IL-12 (BD) of the different conditions. TUNEL staining was performed on macrophages to analyze apoptosis.
###end p 40
###begin title 41
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human carotid plaques.
###end title 41
###begin p 42
###xml 103 118 103 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Ho et al., 1995</xref>
###xml 120 142 120 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Verhoeven et al., 2004</xref>
###xml 273 295 273 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Verhoeven et al., 2004</xref>
###xml 928 949 928 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Hellings et al., 2007</xref>
###xml 1469 1490 1469 1490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Boddaert et al., 2005</xref>
###xml 1241 1253 <span type="species:ncbi:9606">participants</span>
The processing and examination of the dissected atherosclerotic plaques has been described previously (Ho et al., 1995; Verhoeven et al., 2004). All stainings were examined microscopically and plaque characteristics were scored semiquantitatively, as described previously (Verhoeven et al., 2004). In brief, no or minor (categorized as "low") macrophage and SMC infiltration represents absent or minimal staining with few clustered cells, whereas moderate and heavy represent moderate or heavy staining with larger areas of clustered cells (categorized as "high"). The size of the lipid core was estimated as a percentage of total plaque area with a division in three categories: <10% (fibrous plaques), 10-40% (fibroatheromatous plaques), and >40% (atheromatous plaques). Recently, we have demonstrated that our semiquantitative analysis of atherosclerotic plaque histology is well reproducible, both intra- and interobserver (Hellings et al., 2007). 40 carotid atherosclerotic plaques (Table S1) were used for determination of P-Stat3, Stat3, P-Stat1, Stat1, and IL-17 expression. Some of these were also used for immunohistochemical staining. The plaques were from the Athero-Express study, a longitudinal vascular biobank study in which participants provided written informed consent, and the study was approved by the Medical Ethics Committee of the University Medical Center Utrecht. Other plaques used for immunohistochemical staining were previously described (Boddaert et al., 2005).
###end p 42
###begin title 43
Statistical analysis.
###end title 43
###begin p 44
Values are expressed as means +/- SEM. Differences between values were examined using nonparametric Mann-Whitney or Kruskal-Wallis tests and were considered significant at P < 0.05.
###end p 44
###begin title 45
Online supplemental material.
###end title 45
###begin p 46
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 397 404 <span type="species:ncbi:9606">patient</span>
Fig. S1 shows the efficiency of SOCS3 deletion and the effects of SOCS3 deletion or overexpression in T cells on atherosclerosis. Fig. S2 shows regulatory T cell number and function, and cytokine levels in chimeric SOCS-WT and SOCS3-cKO mice. Fig. S3 shows complementary IL-10 and IL-17 supplementation experiments. Fig. S4 shows characterization of the MM17F3 anti-IL-17 antibody. Table S1 shows patient characteristics. Online supplemental material is available at .
###end p 46
###begin title 47
Supplementary Material
###end title 47
###begin title 48
[Supplemental Material]
###end title 48
###begin p 49
###xml 142 145 142 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 138 145 138 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Apoe<sup>&#8722;/&#8722;</sup></italic>
###xml 150 153 150 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 146 153 146 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rag2<sup>&#8722;/&#8722;</sup></italic>
###xml 21 25 <span type="species:ncbi:10090">mice</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 293 297 <span type="species:ncbi:51089">Mace</span>
The IL-17A-deficient mice were provided by Y. Iwakura (University of Tokyo, Tokyo, Japan). We are indebted to P. Gourdy for providing the Apoe-/-/Rag2-/- mice, to R. Merval for help in ELISA measurements, to J. Vilard for expert technical assistance in quantitative PCR experiments, and to D. Mace for his valuable technical support. We are also indebted to M. Pla and M. Chopin for animal care.
###end p 49
###begin p 50
This work was supported by the Institut National de la Sante et de la Recherche Medicale; by the transatlantic Leducq Immunoregulatory Network; the European Union Seventh Framework program TOLERAGE; the European Vascular Genomics Network; the Fund of Scientific Medical Research; the Belgian Federal Service for Scientific Technical and Cultural Affairs (C. Uyttenhove and J. Van Snick); grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; and the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (A. Yoshimura). Z. Mallat is a recipient of a Contrat d'Interface from Assistance Publique-Hopitaux de Paris.
###end p 50
###begin p 51
The authors have no conflicting financial interests.
###end p 51
###begin article-title 52
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Lactadherin defciency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice.
###end article-title 52
###begin article-title 53
T(H)-17 cells in the circle of immunity and autoimmunity.
###end article-title 53
###begin article-title 54
Innate and acquired immunity in atherogenesis.
###end article-title 54
###begin article-title 55
###xml 43 48 <span type="species:ncbi:9606">human</span>
Age and gender effects on apoptosis in the human coronary arterial wall.
###end article-title 55
###begin article-title 56
Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells.
###end article-title 56
###begin article-title 57
TH17 cells in development: an updated view of their molecular identity and genetic programming.
###end article-title 57
###begin article-title 58
###xml 66 71 <span type="species:ncbi:9606">human</span>
Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells.
###end article-title 58
###begin article-title 59
Causes of death in hyper-IgE syndrome.
###end article-title 59
###begin article-title 60
Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo.
###end article-title 60
###begin article-title 61
The immune response in atherosclerosis: a double-edged sword.
###end article-title 61
###begin article-title 62
Intraobserver and interobserver variability and spatial differences in histologic examination of carotid endarterectomy specimens.
###end article-title 62
###begin article-title 63
The Mollring Cutter remote endarterectomy: preliminary experience with a new endovascular technique for treatment of occlusive superficial femoral artery disease.
###end article-title 63
###begin article-title 64
Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta1.
###end article-title 64
###begin article-title 65
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome.
###end article-title 65
###begin article-title 66
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 66 67 66 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 84 85 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgammat+ T cells.
###end article-title 66
###begin article-title 67
Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3.
###end article-title 67
###begin article-title 68
###xml 121 125 <span type="species:ncbi:10090">mice</span>
Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice.
###end article-title 68
###begin article-title 69
###xml 152 156 <span type="species:ncbi:10090">mice</span>
Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice.
###end article-title 69
###begin article-title 70
Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome.
###end article-title 70
###begin article-title 71
Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome.
###end article-title 71
###begin article-title 72
Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis.
###end article-title 72
###begin article-title 73
Interleukin-17 is a negative regulator of established allergic asthma.
###end article-title 73
###begin article-title 74
SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses.
###end article-title 74
###begin article-title 75
IL-17 produced by Paneth cells drives TNF-induced shock.
###end article-title 75
###begin article-title 76
###xml 99 103 <span type="species:ncbi:10090">mice</span>
Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis.
###end article-title 76
###begin article-title 77
Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads.
###end article-title 77
###begin article-title 78
###xml 145 149 <span type="species:ncbi:10090">mice</span>
The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice.
###end article-title 78
###begin article-title 79
Cytokines in atherosclerosis: pathogenic and regulatory pathways.
###end article-title 79
###begin article-title 80
Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis.
###end article-title 80
###begin article-title 81
Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis.
###end article-title 81
###begin article-title 82
Critical aneurysmal dilatation of the thoracic aorta in young adolescents with variant hyperimmunoglobulin E syndrome.
###end article-title 82
###begin article-title 83
###xml 124 131 <span type="species:ncbi:9606">patient</span>
Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design.
###end article-title 83
###begin article-title 84
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.
###end article-title 84
###begin article-title 85
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models.
###end article-title 85
###begin article-title 86
IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages.
###end article-title 86
###begin article-title 87
SOCS proteins, cytokine signalling and immune regulation.
###end article-title 87
###begin p 88
###xml 0 19 0 19 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="89">Abbreviations used:</title>
###xml 19 20 19 20 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</term>
###xml 20 34 20 34 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="90">phosphorylated</p>
###xml 20 34 20 34 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="90">phosphorylated</p></def>
###xml 19 34 19 34 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>P</term><def><p textid="90">phosphorylated</p></def></def-item>
###xml 34 37 34 37 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMC</term>
###xml 37 55 37 55 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="91">smooth muscle cell</p>
###xml 37 55 37 55 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="91">smooth muscle cell</p></def>
###xml 34 55 34 55 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>SMC</term><def><p textid="91">smooth muscle cell</p></def></def-item>
###xml 55 59 55 59 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS</term>
###xml 59 91 59 91 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="92">suppressor of cytokine signaling</p>
###xml 59 91 59 91 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="92">suppressor of cytokine signaling</p></def>
###xml 55 91 55 91 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>SOCS</term><def><p textid="92">suppressor of cytokine signaling</p></def></def-item>
###xml 91 93 91 93 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tg</term>
###xml 93 103 93 103 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="93">transgenic</p>
###xml 93 103 93 103 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="93">transgenic</p></def>
###xml 91 103 91 103 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>Tg</term><def><p textid="93">transgenic</p></def></def-item>
###xml 103 108 103 108 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TUNEL</term>
###xml 108 150 108 150 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="94">Tdt-mediated dUTP-biotin nick-end labeling</p>
###xml 108 150 108 150 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="94">Tdt-mediated dUTP-biotin nick-end labeling</p></def>
###xml 103 150 103 150 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>TUNEL</term><def><p textid="94">Tdt-mediated dUTP-biotin nick-end labeling</p></def></def-item>
###xml 150 154 150 154 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VCAM</term>
###xml 154 185 154 185 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="95">vascular cell adhesion molecule</p>
###xml 154 185 154 185 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="95">vascular cell adhesion molecule</p></def>
###xml 150 185 150 185 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>VCAM</term><def><p textid="95">vascular cell adhesion molecule</p></def></def-item>
###xml 0 185 0 185 <def-list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="89">Abbreviations used:</title><def-item><term>P</term><def><p textid="90">phosphorylated</p></def></def-item><def-item><term>SMC</term><def><p textid="91">smooth muscle cell</p></def></def-item><def-item><term>SOCS</term><def><p textid="92">suppressor of cytokine signaling</p></def></def-item><def-item><term>Tg</term><def><p textid="93">transgenic</p></def></def-item><def-item><term>TUNEL</term><def><p textid="94">Tdt-mediated dUTP-biotin nick-end labeling</p></def></def-item><def-item><term>VCAM</term><def><p textid="95">vascular cell adhesion molecule</p></def></def-item></def-list>
Abbreviations used:PphosphorylatedSMCsmooth muscle cellSOCSsuppressor of cytokine signalingTgtransgenicTUNELTdt-mediated dUTP-biotin nick-end labelingVCAMvascular cell adhesion molecule
###end p 88
###begin title 89
Abbreviations used:
###end title 89
###begin p 90
phosphorylated
###end p 90
###begin p 91
smooth muscle cell
###end p 91
###begin p 92
suppressor of cytokine signaling
###end p 92
###begin p 93
transgenic
###end p 93
###begin p 94
Tdt-mediated dUTP-biotin nick-end labeling
###end p 94
###begin p 95
vascular cell adhesion molecule
###end p 95

